KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Financing Activities (2016 - 2025)

BeOne Medicines (ONC) has disclosed Cash from Financing Activities for 11 consecutive years, with $961.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 7491.79% to $961.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $958.0 million, a 75.77% increase, with the full-year FY2024 number at $193.4 million, down 53.55% from a year prior.
  • Cash from Financing Activities was $961.3 million for Q3 2025 at BeOne Medicines, up from $35.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $3.3 billion in Q4 2021 to a low of -$110.4 million in Q4 2022.
  • A 5-year average of $267.9 million and a median of $35.0 million in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 163.86% in 2023, then surged 7491.79% in 2025.
  • BeOne Medicines' Cash from Financing Activities stood at $3.3 billion in 2021, then tumbled by 103.36% to -$110.4 million in 2022, then soared by 414.45% to $347.0 million in 2023, then tumbled by 101.3% to -$4.5 million in 2024, then surged by 21352.97% to $961.3 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Cash from Financing Activities are $961.3 million (Q3 2025), $35.0 million (Q2 2025), and -$33.8 million (Q1 2025).